Genetic and pharmacological inhibition of KDM5 or SUV39H1 results in increased STING expression and type I IFN production in breast cancer and HPV-transformed cells, respectively, in response to dsDNA treatment [79,80]. The gene discussed is STING1; the disease is breast cancer.